Centre Hospitalier De Perigueux — Clinical Trial Site

29 Registered trials

12 Currently recruiting

Organisation

Centre Hospitalier De Perigueux

Location

Perigueux, France

Identifier

ORG-100043564

Address

80 Avenue Georges Pompidou, 24000, France

Departments

#5026: Hôpital de jour d'Hématologie
cardiology
Department of Oncology and Haematology
Dermatologie
hematologie
Hematology
Infectious disease
Internal Medicine-Immune Hematology Clinic
Maladies Infectieuses
Maladies Infectieuses et Tropicales
Onco-hématologie
Onco-hematology
Oncologie Hématologie
Pneumologie
Service d'oncologie-Hématologie
Service de Malinfectieuses et Tropicales
Service de pneumologie
Service oncologie hématologie
Service Oncologie-Hématologie
SMIT

Clinical trials at this site (29)

Search interface

MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending

2024-513889-19-00 Multiple Myeloma 5
Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplas… Pending

2024-515362-13-00 Philadelphia-negative myeloproliferative neoplasms are 10
Efficacy of an empirical treatment with Amoxicillin-clavulanate (AC) compared to the combination Amoxicillin-clavulanate and Ciprofloxacin (… Pending

2025-520995-24-00 Adult patients treated for haematological disorders, in 5
CPAAARI-Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole al… Recruiting

2024-517004-11-00 Chronic pulmonary aspergillosis 5 2024-10-22
A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso… Recruiting

2024-511855-16-00 Onco-hematology 5 2019-07-25
A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf… Recruiting

2024-516418-39-00 Multiple Myeloma 5 2025-07-09
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p… Recruiting

2024-517325-43-00 multiple myeloma 4 2025-06-19
Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit… Recruiting

2024-510981-18-00 Multiple Myeloma Multiple myeloma (MM) is a B cell mali 5 2024-12-12
Amoxicillin alone versus amoxicillin/clavulanate for community-acquired pneumonia in patients aged 65 years or older, and hospitalized in a … Recruiting

2023-503645-63-00 Patients aged 65 years or older, hospitalized in a non- 5 2024-04-25
Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterre… Recruiting

2024-514952-34-00 Catheter related bloodstream infections due to Staphylo 5 2023-06-23
Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting

2022-501710-62-02 Peripheral T-cell lymphoma (PTCL) 6 2023-06-07
A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting

2024-515354-24-00 Low risk myelodysplastic syndrom without RS having fail 9 2022-05-18
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim… Recruiting

2024-510690-16-00 Relapsed/refractory follicular lymphoma 5 2022-01-31
HEMATOVAC-Immunogenicity of an Anti-pneumococcal Combined Vaccination (PCV13+PPV23 versus PREVENAR20) in Lymphoma Recruiting

2024-517288-22-01 Lymphoma 6 2021-01-29
CLAZI : CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective co… Recruiting

2024-518578-15-00 Is to demonstrate a non inferior efficacy of azithromyc 5 2018-02-05
Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associat… Ended

2024-515433-15-02 acute coronary syndrome 6 2025-01-29
AITIK-Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System Ended

2024-515479-36-00 Chronic Myeloid Leukemia 5 2023-07-05
SC versus IV isatuximab in combination with pomalidomide and dexamethasone in RRMM Ended

2023-508869-32-00 Cancer - Plasma cell myeloma recurrent 5 2022-11-10
RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutane… Ended

2024-516168-27-00 Adult patients with persistent or chronic immune thromb 5 2022-11-10
IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre… Ended

2024-517215-67-00 Newly diagnosed Non-Frail transplant Ineligible Multipl 5 2021-06-11
KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA… Ended

2024-513252-15-00 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL 4 2021-01-28
A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended

2024-514088-25-00 Multiple Myeloma 5 2019-10-07
This is a phase 2, randomized, double blind, multicenter study evaluating the efficacy and safety of the combination of methotrexate plus UV… Ended

2024-512766-34-00 Vitiligo with new lesions or extension of old lesions d 4 2023-04-28
A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended

2022-501901-10-00 Chronic Hepatitis D Infection 6 2023-02-06